Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Zucara Therapeutics, a diabetes life sciences company developing ZT-01, the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, recently announced that it has completed the second and final closing of its US$25 million Series B Financing (the “Financing”). This will enable Zucara Therapeutics to complete their Phase 2a clinical trial and the nonclinical activities to support a once-weekly version of ZT-01.

Zucara Therapeutics is an alumnus of our CAAP® program and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Ontario's Wet Lab Funding Shortage Could Drive Innovation Exodus
Next

Yellowbird Diagnostics Closes an Oversubscribed Funding Round